omada health will prescribe glp-1 drugs starting in 2026. Obesity is a chronic disease needing evidence-based treatment. When the Medicare Bridge program launches July 1, we're here to help patients access the care they deserve. Questions? https://obesitycareadvocacynetwork.com/news/bridgeqa Omada introduces GLP-1 prescribing feature

Through both primary and secondary research , we capture and analyze critical company-level data such as manufacturing footprints, including technical centers, R&D facilities, sales offices, and headquarters

As we extend the use of these medicines in new populations, our clinical experience in those populations will be even thinner, said Drucker

UA has received honoraria from Procter & Gamble, Viatris, Grunenthal and Sanofi for educational meetings

Not All Olive Oils Are Equal: Why Polyphenol Content Matters This is a critical distinction that often gets lost in general dietary advice

Safety Considerations Most common adverse effects: Nausea Vomiting Diarrhea GI intolerance Rare but important: Pancreatitis Gallbladder disease Potential thyroid C-cell concerns in animal models Careful patient selection and dose titration remain essential